.

Deeper Knowledge, Faster

  • Plan your formulary budget
  • Find suppliers and generic API sources
  • Identify first generic entrants

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Express Scripts
AstraZeneca
Harvard Business School
UBS
Moodys
Chubb
Deloitte
Baxter
Cantor Fitzgerald
McKesson

Generated: July 25, 2017

DrugPatentWatch Database Preview

Symplmed Pharms Llc Company Profile

« Back to Dashboard

What is the competitive landscape for SYMPLMED PHARMS LLC, and what generic alternatives to SYMPLMED PHARMS LLC drugs are available?

SYMPLMED PHARMS LLC has two approved drugs.

There are two US patents protecting SYMPLMED PHARMS LLC drugs on SYMPLMED PHARMS LLC drugs in the past three years.

There are sixty-six patent family members on SYMPLMED PHARMS LLC drugs in thirty-seven countries.

Summary for Applicant: Symplmed Pharms Llc

Patents:2
Tradenames:2
Ingredients:2
NDAs:2
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Symplmed Pharms Llc
PRESTALIA
amlodipine besylate; perindopril arginine
TABLET;ORAL205003-001Jan 21, 2015RXYesNo► Subscribe► SubscribeYY ► Subscribe
Symplmed Pharms Llc
PRESTALIA
amlodipine besylate; perindopril arginine
TABLET;ORAL205003-003Jan 21, 2015RXYesYes► Subscribe► Subscribe► Subscribe
Symplmed Pharms Llc
PRESTALIA
amlodipine besylate; perindopril arginine
TABLET;ORAL205003-002Jan 21, 2015RXYesNo► Subscribe► Subscribe► Subscribe
Symplmed Pharms Llc
PRESTALIA
amlodipine besylate; perindopril arginine
TABLET;ORAL205003-001Jan 21, 2015RXYesNo► Subscribe► SubscribeYY ► Subscribe
Symplmed Pharms Llc
ACEON
perindopril erbumine
TABLET;ORAL020184-003Dec 30, 1993DISCNYesNo► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Symplmed Pharms Llc

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Symplmed Pharms Llc
ACEON
perindopril erbumine
TABLET;ORAL020184-003Dec 30, 1993► Subscribe► Subscribe
Symplmed Pharms Llc
ACEON
perindopril erbumine
TABLET;ORAL020184-001Dec 30, 1993► Subscribe► Subscribe
Symplmed Pharms Llc
ACEON
perindopril erbumine
TABLET;ORAL020184-002Dec 30, 1993► Subscribe► Subscribe
Symplmed Pharms Llc
ACEON
perindopril erbumine
TABLET;ORAL020184-003Dec 30, 1993► Subscribe► Subscribe
Symplmed Pharms Llc
ACEON
perindopril erbumine
TABLET;ORAL020184-002Dec 30, 1993► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for SYMPLMED PHARMS LLC drugs

Drugname Dosage Strength Tradename Submissiondate
perindopril arginine and amlodipine
Tablets3.5 mg/2.5 mg, 7 mg/5 mg and 14 mg/10 mg
PRESTALIA
11/4/2016
perindopril erbumine
Tablets2 mg, 4 mg and 8 mg
ACEON
6/6/2006

International Patent Family for Symplmed Pharms Llc Drugs

Country Document Number Estimated Expiration
Malaysia151035► Subscribe
South Africa200807024► Subscribe
Australia2003222921► Subscribe
Canada2423825► Subscribe
European Patent Office1989182► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Symplmed Pharms Llc Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0443983/03Switzerland► SubscribePRODUCT NAME: VALSARTAN + AMLODIPINE + HYDROCHLOROTHIAZIDE; REGISTRATION NUMBER/DATE: SWISSMEDIC 59407 16.09.2009
C0033France► SubscribePRODUCT NAME: ALISKIRENE OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE E CELUI-CI, AMLODIPINE OU SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI, ET HYDROCHLOROTHIAZIDE OU SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI; NAT. REGISTRATION NO/DATE: EU/1/11/730/001 20111122; FIRST REGISTRATION: 6167801 20110705
00625Netherlands► SubscribePRODUCT NAME: COMBINATIE BEVATTENDE ALISKIREN, OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN, EN AMLODIPINE, OF EEN FARMACEUATISCH AANVAARDBAAR ZOUT DAARVAN; REGISTRATION NO/DATE: EU/1/11/686/001-056 20110414
00486Netherlands► SubscribePRODUCT NAME: COMBINATIE VAN OLMESARTANMEDOXOMIL, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, AMLODIPINEBESYLAAT AND HYDROCHLOORTHIAZIDE; NATL REGISTRATION NO/DATE: RVG 106667, RVG 106671-74, RVG 106682-86 20101221; FIRST REGISTRATION: DE 79810.00.00-79814.00.00 20101216
00445Netherlands► SubscribePRODUCT NAME: VALSARTAN, AMLODIPINE EN HYDROCHLOORTHIAZIDE EN FARMACEUTISCH AANVAARDBARE ZOUTEN DAARVAN; REGISTRATION NO/DATE: EU/1/09/569/001-060 20091016
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Teva
UBS
Citi
US Department of Justice
Colorcon
McKinsey
Boehringer Ingelheim
Farmers Insurance
Deloitte
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot